Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient [Corrigendum]
Tanino Y, Nishioka K, Yamamoto C, et al. Infect Drug Resist. 2024:17:531–541. Our authors have advised that there are two sentences that needed revision in the abstract section of the published paper. E340A/V792I is incorrectly described as E340K/V791I. The second sentence in “...
Main Authors: | Tanino Y, Nishioka K, Yamamoto C, Watanabe Y, Daidoji T, Kawamoto M, Uda S, Kirito S, Nakagawa Y, Kasamatsu Y, Kawahara Y, Sakai Y, Nobori S, Inaba T, Ota B, Fujita N, Hoshino A, Nukui Y, Nakaya T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2024-03-01
|
Series: | Infection and Drug Resistance |
Subjects: | |
Online Access: | https://www.dovepress.com/corrigendum-emergence-of-sars-cov-2-with-dual-drug-resistant-mutations-peer-reviewed-fulltext-article-IDR |
Similar Items
-
Emergence of SARS-CoV-2 with Dual-Drug Resistant Mutations During a Long-Term Infection in a Kidney Transplant Recipient
by: Tanino Y, et al.
Published: (2024-02-01) -
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
by: Ivan Gentile, et al.
Published: (2023-12-01) -
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
by: Simona Biscarini, et al.
Published: (2022-08-01) -
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
by: Supavit Chesdachai, et al.
Published: (2024-03-01) -
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants
by: Kana Fujimoto, et al.
Published: (2022-12-01)